CLCD Colucid Pharmaceuticals Inc

COLUCID PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

Rigrodsky & Long, P.A.:

  • Do you own shares of CoLucid Pharmaceuticals, Inc. (NASDAQ GM: CLCD)?
  • Did you purchase any of your shares prior to January 18, 2017?
  • Do you think the proposed buyout price is too low?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of CoLucid Pharmaceuticals, Inc. (“CoLucid” or the “Company”) (NASDAQ GM: CLCD) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Eli Lilly and Company (“Eli Lilly”) (NYSE: LLY), in a transaction valued at approximately $960 million.

Click here to learn more: http://rigrodskylong.com/investigations/colucid-pharmaceuticals-inc-clcd.

Under the terms of the agreement, shareholders of CoLucid will receive $46.50 in cash for each share of CoLucid common stock.

The investigation concerns whether CoLucid’s board of directors failed to adequately shop the Company and obtain the best possible value for CoLucid shareholders before entering into an agreement with Eli Lilly.

If you own the common stock of CoLucid and purchased your shares before January 18, 2017, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail to [email protected], or at: http://rigrodskylong.com/investigations/colucid-pharmaceuticals-inc-clcd.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

EN
18/01/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Colucid Pharmaceuticals Inc

GlobalData Healthcare Department
  • GlobalData Healthcare Department

CoLucid Pharmaceuticals Inc (CLCD) - Pharmaceuticals & Healthcare - De...

Summary CoLucid Pharmaceuticals Inc (CoLucid) is a pharmaceutical company that conducts research and develops new therapies. CoLucid’s lead product candidate Lasmiditan (COL-144), is an oral tablet that penetrates the central nervous system and selectively targets 5-HT1F receptors expressed in the trigeminal nerve pathway. It’s been designed to deliver efficacy for the acute treatment of migraine in adults without the vasoconstrictor activity and clinical limitations associated with previou...

 PRESS RELEASE

INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Conce...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD) stock prior to January 18, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. (NYSE: LLY). Under the terms of the transaction (valued at approximately $960 Million) CoLucid Pharmaceuticals, Inc. shareholders will receive $...

 PRESS RELEASE

Bragar Eagel & Squire, P.C. Is Investigating the Board of Directors of...

NEW YORK--(BUSINESS WIRE)-- Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of CoLucid Pharmaceuticals (NASDAQ:CLCD) stockholders concerning the proposed acquisition of the company by Eli Lilly and Company. CoLucid Pharmaceuticals is a Phase 3 clinical-stage biopharmaceutical company that is developing an oral 5-HT1F agonist (lasmiditan) for the acute treatment of migraine. The investigation concerns whether CoLucid’s board of directors failed to adequately shop the Company and obtain the best...

 PRESS RELEASE

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Propo...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of CoLucid Pharmaceuticals, Inc. (Nasdaq: CLCD) (“CoLucid” or the “Company”) relating to the proposed buyout of CoLucid by Eli Lilly and Company. Under the terms of the agreement, CoLucid shareholders are anticipated to receive $46.50 in cash for each share of CoLucid common stock hel...

 PRESS RELEASE

INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Conce...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD) stock prior to January 18, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. (NYSE: LLY). Under the terms of the transaction (valued at approximately $960 Million) CoLucid Pharmaceuticals, Inc. shareholders will receive $...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch